HIV AIDS STD & STIs"

Pharma Business of HIV/AIDS, STDs & STIs

Global HIV Drug Market was valued at $20,448 million in 2015 and is expected to increase till $26,458 million by 2022, registering a CAGR of 3.7% during the forecast period 2016-2022. Human immunodeficiency virus (HIV) is one of the most infectious diseases with around 36.7 million people suffering by the end of 2015. The major factors that boost the HIV drug market growth include increase in prevalence of HIV and rise in treatment & diagnosis rate. Moreover, there is an increase in the government initiative to increase awareness among people about HIV cause, symptoms, available treatment options, and the crucial role of these treatments in the control of HIV virus growth. Thus, rise in awareness through such government initiatives are also expected to drive the HIV drugs market. However, a stringent government regulation for the approval and commercialization of HIV drugs is expected to restrain the industry growth.